Validity of HAT Score for Predicting Symptomatic Intracranial Hemorrhage in Acute Stroke Patients with Proximal Occlusions: Data from Randomized Trials of Sonothrombolysis

Georgios Tsivgoulis a,e, Maher Saqqur c, Andrew Barreto b, Andrew M. Demchuk d, Marc Ribó g, Marta Rubiera g, Vijay K. Sharma h, Elefterios Stamboulis f, Peter D. Schellinger i, Carlos A. Molina g, Andrei V. Alexandrov a

a Comprehensive Stroke Center, University of Alabama at Birmingham Hospital, Birmingham, Ala., and b Stroke Program, The University of Texas-Houston Medical School, Houston, Tex., USA; c Division of Neurology, University of Alberta Medical School, Edmonton, Alta., and d Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alta., Canada; e Department of Neurology, Democritus University of Thrace, Alexandroupolis, and f Second Department of Neurology, University of Athens, School of Medicine, Athens, Greece; g Department of Neurology, Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; h Division of Neurology, Department of Medicine, National University Hospital, Singapore; i Department of Neurology, University Hospital of Erlangen, Erlangen, Germany

Abstract

Background: The Hemorrhage after Thrombolysis (HAT) score has recently been introduced as a practical scale for risk stratification of intracranial hemorrhage (ICH) in patients receiving intravenous tissue plasminogen activator (tPA). We aimed to externally validate and evaluate the predictive ability of the HAT score in patients with proximal arterial occlusions (PAO) enrolled into randomized clinical trials of sonothrombolysis. Methods: The HAT score (range 0, minimum risk, to 5, maximum risk) was retrospectively calculated for each patient using clinical trial data (baseline NIHSS, extent of hypodensity on CT, history of diabetes mellitus and serum glucose). Symptomatic ICH (sICH) was defined as imaging evidence of ICH with clinical worsening (NIHSS ≥ 4) within 72 h from stroke onset. The predictive ability of the HAT score for sICH and any ICH (both asymptomatic and symptomatic) was calculated using c statistics. Results: A total of 161 tPA-treated patients (mean age 68 ± 13 years, 58% men, median NIHSS 16, interquartile range 9) with PAO were randomized in TUCSON (n = 35) and CLOTBUST (n = 126). sICH occurred in 9 (5.6%) cases, and 6 had asymptomatic ICH. The rates of sICH for the corresponding HAT scores were: HAT 0–1: 3%; 2: 9%; 3: 14%; 4–5: 14%. The risk of sICH (c statistic 0.72, 95% CI: 0.58–0.86; p = 0.027) and any ICH (c statistic 0.70, 95% CI: 0.58–0.82; p = 0.011) increased with higher HAT scores. Higher HAT scores were also associated with higher likelihood of persisting occlusion (c statistic 0.63, 95% CI: 0.54–0.72; p = 0.004). Conclusions: The HAT score has reasonable external validity for predicting the risk of sICH following intravenous thrombolysis in patients with PAO. Moreover, higher HAT scores appear to be associated with higher likelihood of persisting occlusion in tPA-treated patients.

Key Words

Thrombolysis · Symptomatic intracranial hemorrhage · Stroke · Occlusion
Introduction
Symptomatic intracranial hemorrhage (sICH) is the most unfavorable and feared complication of intravenous thrombolysis and the most important factor deterring the use of intravenous tissue plasminogen activator (iv-tPA) in patients with acute ischemic stroke [1]. The most consistently identified predictors of sICH in acute revascularization trials using thrombolytic therapies have been the dose of lytic agents, edema or mass effect on head CT and stroke severity [2]. Other risk factors that may be associated with sICH include older age, hyperglycemia, concurrent heparin use, timing of therapy, and timing of recanalization [1, 2].

The Hemorrhage after Thrombolysis (HAT) score has recently been introduced as a practical scale for risk stratification of intracranial hemorrhage (ICH) in patients receiving iv-tPA [3]. The main advantages of this practical scale are related to its wide applicability and the easiness to perform since the computation of the score is based on baseline stroke severity, extent of hypodensity on admission CT scan and baseline serum glucose or history of diabetes mellitus. However, its predictive ability has not been externally validated or tested in patients with acute proximal arterial occlusions. We aimed to externally validate HAT scores in patients with acute proximal intracranial arterial occlusions enrolled in randomized clinical trials of sonothrombolysis [4, 5].

Methods
We retrospectively analyzed data collected from patients who were enrolled in CLOTBUST (Combined Lysis of Thrombus in Brain Ischemia using transcranial Ultrasound and Systemic TPA) [4] and TUCSON (Transcranial Ultrasound in Clinical SO-Notrombolysis) [5], two phase II trials of ultrasound-enhanced thrombolysis. Patients were considered eligible for CLOTBUST and TUCSON only when they had transcranial Doppler (TCD) evidence of an acute proximal intracranial arterial occlusion. In both trials, arterial occlusions were diagnosed using Thrombolysis in Brain Ischemia (TIBI) flow grades [6]. TIBI flow grades were previously validated against invasive angiography with an excellent (90–100%) agreement, particularly for the proximal middle cerebral artery (MCA) occlusion location as well as determining persisting occlusion, partial or complete recanalization [6–12]. Pretreatment stroke severity was evaluated in both trials using the NIH Stroke Scale Score (NIHSS score), while blood glucose values were measured in all patients at hospital admission. All patients received standard iv-tPA therapy (0.9 mg/kg dose, maximum 90 mg, 10% bolus, 90% continuous infusion for 1 h following bolus injection) that was initiated within the first 3 h after symptom onset according to published criteria [13].

The HAT score (range 0, minimum risk, to 5, maximum risk) was retrospectively calculated for each patient using prospectively collected data for the following clinical and neuroimaging variables: pretreatment NIHSS (<15: 0 point; 15–20: 1 point; >20: 2 points), history of diabetes mellitus or baseline serum glucose >200 mg/dl upon admission (1 point) and presence of early visible hypodensity on initial brain CT scan (absence of hypodensity: 0 point, <1/3 of MCA territory: 1 point; ≥1/3 MCA territory: 2 points) [3].

sICH was diagnosed using the definition that was adopted by investigators prior to clinical trial initiation: imaging evidence of ICH with clinical worsening (NIHSS increase of 4 or more points from baseline assessment) within 72 h from stroke onset [4]. In case of doubt with regard to whether edema or hemorrhage was the leading pathology causing the clinical deterioration (increase of ≥4 points in NIHSS score), an association of the hemorrhage with deterioration was invariably assumed in order to avoid missing any sICH cases, since CLOTBUST and TUCSON were phase II safety and feasibility trials. Consequently, sICH was diagnosed in all patients with a clinical deterioration of 4 or more points in the NIHSS score and brain imaging evidence of ICH, independent of the presence of causality between clinical deterioration and ICH in each case. There was no central adjudication for sICH in CLOTBUST [4]. The treating physicians at the four centers, who were experienced stroke neurologists, made this diagnosis. In TUCSON a site investigator blinded to the treatment allocation made the diagnosis of sICH. A central reader who was also blinded to the treatment group confirmed all cases. In addition, the central reader reviewed the baseline and repeat CT scans of all patients enrolled in the TUCSON trial in order to detect the presence of any intracranial bleed that may have been missed by the site investigator [5].

Asymptomatic ICH (aICH) was defined as imaging evidence of ICH (hemorrhagic transformation or parenchymal hematoma) without clinical worsening (NIHSS increase of 3 or less points from baseline assessment) [5]. Persisting occlusion, partial and complete recanalization were diagnosed on the basis of our validated TIBI flow grading system at the end of TCD monitoring as previously described [6–12]. Patients with recollapse during TCD monitoring were diagnosed as having persisting occlusion at the end of TCD monitoring [4, 5, 14]. Favorable functional outcome was defined as a modified Rankin Scale score of 0–2 at 3 months after treatment [3–5]. Further details regarding the protocols of both trials have previously been published [15, 16]. In order to be able to make direct comparisons with previous studies we also used the definition of the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST) for sICH and repeated all analyses [17].

Statistical Analyses
Statistical comparisons were performed between patient groups stratified by the HAT score using the χ² test, Fisher’s exact test, unpaired t test, and Mann-Whitney U test as indicated for dichotomous or continuous variables. The adjusted Wald method, which provides the best coverage for binomial confidence intervals (CI) when samples are less than 150 [18], was used for computation of 95% CI for the sICH rates across the different HAT-score subgroups. We evaluated the predictive ability of the score for detection of sICH, any ICH (combination of aICH and sICH), persisting occlusion and favorable functional outcome at
3 months using receiver operating characteristic curve models. In addition, accuracy parameters (sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy) were determined at each cutoff of the score for the different outcome variables. Areas under receiver-operator curves (c statistic) and corresponding 95% CIs were calculated as a measure of predictive ability. The c statistic integrates sensitivity and specificity of the range of a variable, and estimates how well a prediction rule can correctly rank-order patients by risk. Ideal prediction produces a c statistic of 1.00; prediction no better than chance is associated with a c statistic of \( \approx 0.50 \). The Statistical Package for Social Science (SPSS Inc., version 13.0 for Windows) was used for statistical analyses.

### Results

A total of 161 iv-tPA-treated patients (mean age 68 ± 13 years, 58% men, median NIHSS 16, interquartile range 9) with proximal arterial occlusions were enrolled in TUCSON (n = 35) and CLOTBUST (n = 126). The baseline characteristics, the ultrasonographic and neuroimaging findings of the study population are summarized in table 1. Sustained complete recanalization was present in 53 patients at the end of TCD monitoring (33%), while persisting occlusion was identified in 64 cases (40%). sICH occurred in 9 (5.6%) cases (6 in CLOTBUST and 3 in TUCSON), and 6 patients (3.7%) had aICH (3 in CLOTBUST and 3 in TUCSON). When the SITS-MOST definition was used for the documentation of sICH, the same 9 cases also met SITS-MOST criteria for symptomatic intracranial bleeding. The rate of sICH was similar in the group receiving sonothrombolysis (7%, 6/86) and iv-tPA alone (4%, 3/75; \( p = 0.505 \) by Fisher’s exact test). The median HAT score was 1 (interquartile range 2). The median HAT score did not differ between the ultrasound-enhanced thrombolysis (1, interquartile range 2) and intravenous thrombolysis groups (1, interquartile range 1; \( p = 0.779 \) by Mann-Whitney U test).

### Table 1. Baseline characteristics, ultrasonographic and neuroimaging findings of the study population (n = 161)

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>TUCSON, n = 35</th>
<th>CLOTBUST, n = 126</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD), years</td>
<td>68 (13)</td>
<td>68 (13)</td>
</tr>
<tr>
<td>Male gender, n</td>
<td>22%</td>
<td>78%</td>
</tr>
<tr>
<td>Diabetes mellitus, n</td>
<td>24%</td>
<td>28%</td>
</tr>
<tr>
<td>Median baseline NIHSS (IQR)</td>
<td>16 (9)</td>
<td>16 (9)</td>
</tr>
<tr>
<td>Median baseline serum glucose</td>
<td>121 (55)</td>
<td>121 (55)</td>
</tr>
<tr>
<td>Median HAT (IQR)</td>
<td>1 (2)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>sICH, n</td>
<td>9 (5.6%)</td>
<td>6 (3.7%)</td>
</tr>
<tr>
<td>aICH, n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained complete recanalization</td>
<td>53 (33%)</td>
<td></td>
</tr>
<tr>
<td>Persisting occlusion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IQR = Interquartile range. \(^1\) At the end of TCD monitoring.

### Table 2. Risk of sICH stratified according to HAT scores in the study population (n = 161)

<table>
<thead>
<tr>
<th>HAT score</th>
<th>sICH, n</th>
<th>sICH risk, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1</td>
<td>3</td>
<td>3 (0–9)</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>9 (0–21)</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>14 (0–53)</td>
</tr>
<tr>
<td>4–5</td>
<td>1</td>
<td>14 (0–53)</td>
</tr>
</tbody>
</table>

\(^1\) \( p \) for linear trend = 0.024. \(^2\) Computed by the adjusted Wald method [14].

### Table 3. Predictive ability of HAT scores for detecting sICH, any ICH, persisting occlusion and favorable functional outcome at 3 months

<table>
<thead>
<tr>
<th>Variable</th>
<th>c statistic (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>sICH</td>
<td>0.72 (0.58–0.86)</td>
<td>0.027</td>
</tr>
<tr>
<td>Any ICH</td>
<td>0.70 (0.58–0.82)</td>
<td>0.011</td>
</tr>
<tr>
<td>Persisting occlusion</td>
<td>0.63 (0.55–0.72)</td>
<td>0.004</td>
</tr>
<tr>
<td>Favorable functional outcome at 3 months</td>
<td>0.76 (0.68–0.84)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Death at 3 months</td>
<td>0.69 (0.59–0.80)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Validation of HAT Score for sICH Risk Prediction
curacy (88%), specificity (92%) and PPV (14%), similar NPV (95%) and lower sensitivity (22%).

There were 6 cases with hypodensity ≥1/3 MCA territory on their baseline CT scan, and 1 sICH (17%) occurred in this subgroup. Since visible hypodensity exceeding 1/3 of the MCA territory is considered a contraindication to thrombolysis in many centers, we repeated our analyses after excluding these 6 patients. The predictive ability of the HAT score for detecting sICH remained practically unchanged (c statistic 0.70, 95% CI: 0.56–0.82; p = 0.046).

Higher HAT scores were also found to be predictive of persisting occlusion (c statistic 0.63, 95% CI: 0.54–0.72; p = 0.004; table 3). Finally, the HAT score reasonably predicted favorable functional outcome at 3 months (c statistic 0.76, 95% CI: 0.68–0.84; p < 0.001; table 3). Higher HAT scores were also predictive of death at 3 months (c statistic 0.69, 95% CI: 0.59–0.80; p = 0.005; table 3).

Discussion

We attempted to evaluate the external validity of the HAT score using prospectively and independently collected sICH data from two phase II randomized trials of sonothrombolysis. Interestingly, we documented similar c statistics to those reported in the study [3] introducing the HAT score for all outcome variables including sICH (0.72 vs. 0.74), any ICH (0.70 vs. 0.72) and 3-month favorable functional outcome (0.76 vs. 0.75). The present study findings are also in line with the results of a Spanish study that has recently been presented at the International Stroke Conference 2010 [19]. The investigators retrospectively analyzed data from a prospective registry of patients treated with tPA in two centers. They documented that higher HAT scores were independently associated with higher likelihood of sICH (OR: 1.5, 95% CI: 1.1–2.0; p = 0.005), hemorrhagic transformation (OR: 1.8, 95% CI: 1.5–2.1; p < 0.001) and poor functional outcome (OR: 3.0, 95% CI: 2.4–3.7; p < 0.001) defined as a modified Rankin Scale score of ≥2. Unfortunately, the predictive ability of the HAT score was not evaluated using c statistics and therefore their data cannot be directly compared to our dataset.

Given the fact that all elements comprising the HAT score have previously been associated with a higher likelihood of persisting occlusion [20–25], we also investigated the potential relationship of this risk stratification scale with the odds of persisting occlusion on TCD monitoring during the first 2 h following a tPA bolus. The detected association of higher HAT scores with an increased risk of persisting occlusion is in full agreement with previous observations from our collaborative group. More specifically, higher NIHSS scores represent a higher clot burden and have been repeatedly documented to substantially decrease the likelihood of recanalization in patients treated with intravenous thrombolysis [4]. In addition, hyperglycemia is a well-known inhibitor of fibrinolysis [26] and it has been constantly shown to hamper recanalization, thus increasing the likelihood of persisting occlusion in different iv-tPA registries monitoring recanalization in real time with TCD [21, 22]. Finally, early ischemic changes on brain CT scans quantified by the Alberta Stroke Program Early CT Score have previously been associated with lower likelihood of complete recanalization and functional independence following intravenous thrombolysis [23, 25].

Our findings indicate that the potential clinical applicability of the HAT score may be related to its high NPV (95%) and specificity (92%) for ruling out sICH in patients with HAT scores less than 3. Consequently, it may serve as a complementary tool to clinical bedside evaluation for the selection of acute ischemic stroke patients with minimal risk of symptomatic intracranial bleeding following intravenous thrombolysis, especially in stroke centers with limited experience with tPA treatment. In contrast, the poor sensitivity and PPV of the HAT score suggest that potential candidates for iv-tPA should not be excluded from this treatment solely on the basis of high HAT scores. More specifically, in our series the rate of sICH was 14% in patients with HAT score ≥3, while in the study introducing the HAT score the risk was 3 times higher (42%), indicating that patients in this specific range of the HAT score (4–5) carry an unacceptable risk of symptomatic intracranial bleeding following intravenous thrombolysis [3]. The discrepant findings between the two studies in this specific subgroup of patients (HAT score: 4–5) may be related to the limited sample size both in our (n = 7) and the combined NINDS/Boston (n = 9) cohort and call for independent validation in larger datasets. Nevertheless, the high specificity and NPV documented in both studies highlight that calculation of the HAT score in everyday clinical practice may offer reassurance to reluctant and relatively inexperienced physicians that patients with HAT scores ≤2 carry low risk for sICH and this may facilitate the wider implementation of intravenous thrombolysis, especially in community centers.

Certain limitations of the present report need to be acknowledged. For one, this is a retrospective analysis of prospectively collected data. In addition, our sample size
is moderate and further independent validation of this score in larger cohorts of patients is required before considering its potential application in clinical practice. More specifically, some of the HAT scores, especially ≥3 points, had very few patients in each category, suggesting that a great deal of imprecision may exist at these levels, with potential variance due to case misclassification. In addition and perhaps related to the previous point about low numbers of observations, the rate of sICH (14%) was the same in the HAT group with 3 points and with 4–5 points, suggesting that some of the parameters included in the score may not add substantially to its predictive value or that a ceiling effect may exist with higher HAT scores.

Also, our study population encompasses patients with proximal arterial occlusions; therefore our results cannot be generalized to patients with distal arterial occlusions or lacunar strokes. It should also be noted that the accuracy parameters of TCD are less reliable than the gold standard (digital subtraction angiography) and are largely dependent on the experience and training of the sonographers [27]. Besides, the reported rate of aICH (3.7%) is low compared to other studies and this may be related to the fact that T2-weighted MRI was not used for ICH detection and therefore some subtle aICHs may have been missed on conventional CT scans. Another potential explanation may be related to the lack of central adjudication of brain CT scan interpretation in CLOTBUST where only 3 aICHs were detected out of a sample of 126 subjects.

In conclusion, our study externally validates the predictive ability of the HAT score for detecting sICH (independent of the definition used) in a subgroup of patients with acute proximal intracranial occlusions treated with iv-tPA. Additionally, higher HAT scores were also predictive of persisting occlusion at the end of TCD monitoring and poor functional outcome at 3 months following onset. Although the former association is intriguing, it may serve only for hypothesis generation and warrants further independent validation in prospective iv-tPA registries.

Disclosure Statement

Dr. Tsivgoulis received a fellowship grant from the Neurology Department, Eginition Hospital, University of Athens School of Medicine, Athens, Greece. Dr. Tsivgoulis and Dr. Alexandrov had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of data analysis. Dr. Saqpur was the Principal Investigator at Edmonton site for the CLOTBUST trial. Dr. Barreto was the Principal Investigator at Houston site for the TUCSON trial. Dr. Demchuk was the Principal Investigator at Calgary site for the CLOTBUST trial. Dr. Ribo none. Dr. Rubiera received a fellowship grant from the Instituto de Salud Carlos III and Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain. Dr. Sharma none. Dr. Stamboulis none. Dr. Schellinger received speaker honoraria from Boehringer Ingelheim, the manufacturer of rt-PA and served as a consultant for ImaRx Therapeutics, Inc. Dr. Molina served as the Principal Investigator for the Barcelona site for the CLOTBUST trial and as the Principal Investigator of the TUCSON trial. Dr. Andrei Alexandrov was the Principal Investigator of the CLOTBUST trial, study director of the TUCSON trial, serves on the speaker bureau of Genentech, Inc., and develops novel technologies under his patent on ultrasound-enhanced thrombolysis for stroke.

References


